Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of HBM9161 in generalized myasthenia gravis
ChiCTR2200059452Phase 3Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of batoclimab in myasthenia gravis (MG) (2 arms), sponsored by Huashan Hospital. Primary endpoint: Incidence of adverse events during the study. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
batoclimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2200059452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059452.